Title: A genome-wide association study of anorexia nervosa.
A genome-wide association study of anorexia nervosa

A full list of authors and affiliations appears at the end of the article.

Abstract

Anorexia nervosa (AN) is a complex and heritable eating disorder characterized by dangerously low body weight. Neither candidate gene studies nor an initial genome wide association study (GWAS) have yielded significant and replicated results. We performed a GWAS in 2,907 cases with AN from 14 countries (15 sites) and 14,860 ancestrally matched controls as part of the Genetic Consortium for AN (GCAN) and the Wellcome Trust Case Control Consortium 3 (WTCCC3). Individual association analyses were conducted in each stratum and meta-analyzed across all 15 discovery datasets. Seventy-six (72 independent) SNPs were taken forward for in silico (two datasets) or de novo (13 datasets) replication genotyping in 2,677 independent AN cases and 8,629 European ancestry controls along with 458 AN cases and 421 controls from Japan. The final global meta-analysis across discovery and replication datasets comprised 5,551 AN cases and 21,080 controls. AN subtype analyses (1,606 AN restricting; 1,445 AN binge-purge) were performed. No findings reached genome-wide significance. Two intronic variants were suggestively associated: rs9839776 (P=3.01×10^{-7}) in SOX2OT and rs17030795 (P=5.84×10^{-6}) in PPP3CA. Two additional signals were specific to Europeans: rs1523921 (P=5.76×10^{-6}) between CUL3 and FAM124B and rs1886797 (P=8.05×10^{-6}) near SPATA13. Comparing discovery to replication results, 76% of the effects were in the same direction, an observation highly unlikely to be due to chance (P=4×10^{-6}), strongly suggesting that true findings exist but that our sample, the largest yet reported, was underpowered for their detection. The accrual of large genotyped AN case-control samples should be an immediate priority for the field.

Keywords

anorexia nervosa; eating disorders; GWAS; genome-wide association study; body mass index; metabolic

*These authors contributed equally to this manuscript
**These authors contributed equally to this manuscript as investigators
+These authors contributed equally to this manuscript

Conflicts of Interest: Patrick F. Sullivan was on the SAB of Expression Analysis (Durham, NC).
Cynthia Bulik was a consultant for Shire Pharmaceuticals at the time the manuscript was written.
Federica Tozzi was full time employee of GSK at the time when the study was performed.
David A. Collier was employed by Eli Lilly UK for a portion of the time that this study was performed.
James L. Kennedy has received honoraria from Eli Lilly and Roche.
Robert D. Levitan has received honorarium from Astra-Zeneca.

Supplementary information is available at Molecular Psychiatry's website.
Introduction

Anorexia nervosa (AN) is a perplexing biologically-influenced psychiatric disorder characterized by the maintenance of dangerously low body weight, fear of weight gain, and seeming indifference to the seriousness of the illness. AN affects ∼1% of the population. Females are disproportionately afflicted, although males also develop the condition. The most common age of onset is 15-19 years; however, the incidence appears to be increasing in the pre-pubertal period and in older adults. AN is often comorbid with major depressive disorder, anxiety disorders, and multiple somatic complications. Although most individuals recover, ∼25% develop a chronic and relapsing course. AN ranks among the ten leading causes of disability among young women and has one of the highest mortality rates of any psychiatric disorder. The evidence base for treatment for AN has been described as “weak” and treatment and extended inpatient hospitalizations for weight restoration are costly. In sum, the public health impact of AN is considerable, and AN carries substantial morbidity, mortality, and personal, familial, and societal costs.

As with most idiopathic psychiatric disorders, the inheritance of AN is complex. The core features of AN [i.e., the ability and determination to maintain low body mass index (BMI)] are remarkably homogeneous across time and cultures. Genetic epidemiological studies have documented the familiality of AN (relative risk 11.3 in first-degree relatives of AN probands) and the estimated twin-based heritability of AN ranges from 33 to 84%. Genome-wide linkage studies did not narrow the genomic search space in a compelling manner. Findings from candidate gene studies of AN resemble those for most complex biomedical diseases—initial intriguing findings diminished by the absence of rigorous replication.

Given the centrality of weight dysregulation to AN, genes implicated in the regulation of body weight might also be involved in the etiology of AN. Therefore genetic variants with a profound effect on BMI are worthy of consideration.

Two genome-wide association studies (GWAS) of AN have been conducted. One study that used DNA pooling and genotyping with a modest number of microsatellite markers with follow-up genotyping detected evidence for association with rs2048332 on chromosome 1, but this finding did not reach genome-wide significance. A GWAS of 1033 AN cases from the USA, Canada, and Europe compared with 3733 pediatric controls yielded no genome-wide significant findings. Recently, a sequencing and genotyping study of 152 candidate genes in 1205 AN cases and 1948 controls suggested a novel association of a cholesterol metabolism influencing EPHX2 gene with susceptibility to AN.

In recognition of the need for large-scale sample collections to empower GWAS, we established the Genetic Consortium for Anorexia Nervosa (GCAN) in 2007—a worldwide collaboration combining existing DNA samples of AN patients into a single resource. As part of the Wellcome Trust Case Control Consortium 3 (WTCC3), we have conducted the largest GWAS for AN to date.
Materials and Methods

Discovery dataset

We conducted a GWAS across 15 discovery datasets, comprising a total of 2,907 AN cases and 14,860 ancestrally matched controls of European origin (Table 1). All AN cases were female. Diagnostic determination was via semi-structured or structured interview or population assessment strategy based on DSM diagnostic criteria. Cases met DSM-IV criteria for lifetime AN (restricting or binge-purge subtype) or lifetime DSM-IV eating disorders “not otherwise specified” (EDNOS) AN-subtype (i.e., exhibiting the core features of AN). We did not require the presence of amenorrhea as this criterion does not increase diagnostic specificity.\textsuperscript{44, 45} Given the frequency of diagnostic crossover, a lifetime history of bulimia nervosa was allowed.\textsuperscript{46} Exclusion criteria included the diagnosis of medical or psychiatric conditions that might have confounded the diagnosis of AN (e.g., psychotic disorders, mental retardation, or a medical or neurological condition causing weight loss). Controls were carefully selected to match for ancestry within each site and chosen primarily from existing GWAS genotypes through collaboration and genotyping repository (dbGAP) access. Each site obtained ethical approval from the local ethics committee, and all participants provided written informed consent in accordance with the Declaration of Helsinki.

Genotyping, imputation and quality control

AN cases from the 15 sites were genotyped using Illumina 660W-Quad arrays (Illumina, Inc., San Diego, CA, USA) at the Wellcome Trust Sanger Institute. Funding was available only for genotyping AN cases. Thus, control genotypes were selected from existing datasets matched as closely as possible to the ancestry of cases and Illumina arrays as similar as possible to the 660W array (Table S1). Quality control (QC) of directly typed variants was performed within each of the 15 case-control datasets (Table S2, Supplementary Information).

Phasing and imputation was performed separately for each of the 15 datasets using a common set of single nucleotide polymorphisms (SNPs) passing QC (Table S2) using the program Impute2 v2.1.2 (Supplementary Information).\textsuperscript{47} The imputation reference panel was HapMap 3 release 2. We used all available HapMap3 populations for imputation as it was shown that the increase in the reference panel decreases error.\textsuperscript{48, 49} Post-imputation filters were applied to remove SNPs with INFO scores < 0.4 or with MAF < 0.05. We observe high imputation accuracy (as captured by the INFO score) across a range of minor allele frequencies (Figure S1). There was high concordance between directly genotyped variants with imputed dosages of the same variants after masking (Figure S2).

Statistical analysis

Single-SNP association analyses were performed under an additive genetic model separately within each of the 15 datasets (Supplementary Information). We tested for association across the autosomes and the non-pseudoautosomal region of the X chromosome. Imputation and association analysis of the non-pseudoautosomal region of the chromosome X data were based on females (2,907 AN cases and 10,594 controls). Association analyses were
performed using SNPTEST v2.2.0 under an additive model and using a score test. To guard against false positives due to population stratification, we carried out association analysis within each dataset and then combined the results using meta-analysis (for the French dataset, the first principal component was added as a covariate). Fixed-effects meta-analyses were performed using GWAMA. All 15 discovery datasets were corrected for the genomic control (GC) inflation factor (\( \lambda_{GC} \)) prior to performing meta-analysis (Table S2; Supplementary Information).

**Replication**

We prioritized directly genotyped and imputed SNPs for replication based on statistical significance (\( P < 10^{-4} \)), robust QC metrics, and vicinity to plausible candidate genes. In total 96 SNPs (95 autosomal and one on chromosome X) in 66 genomic regions showed nominal evidence for association. We selected 72 independent, uncorrelated variants representing each of the 66 associated genomic regions and added 4 proxies for the most associated SNPs resulting in 76 SNPs for replication. Cluster plots of all prioritized SNPs were examined using Evoker in cases and controls separately to minimize the possibility of spurious association due to genotyping error. We included 27 ancestry-informative markers (AIMs) for genotyping in the replication datasets, to guard against population stratification (Supplementary Information).

Our replication data included 15 datasets—two existing *in silico* datasets and 13 datasets for *de novo* genotyping (Table 1). The *in silico* dataset from the USA came from an existing GWAS of AN genotyped using the Illumina HumanHap610 platform (Illumina, San Diego, CA, USA) and the other *in silico* dataset came from Estonian Genome Center (www.biobank.ee) and was genotyped using the Illumina OmniExpress array. *De novo* genotyped samples included newly collected AN cases and controls from members of the GCAN and samples from the same sites as the discovery samples that had failed GWAS QC (including saliva and whole genome amplified samples). *De novo* SNP genotyping was carried out using the iPLEX Gold Assay (Sequenom, Inc., San Diego, CA, USA). SNPs with poor Sequenom design metrics were replaced with high-LD proxies. Sample and SNP QC were performed within each replication dataset. QC included checking for sex inconsistencies and exclusions based on sample call rate <80%, SNP call rate <90% and exact Hardy-Weinberg Equilibrium (HWE) \( p<0.0001 \). In total, replication genotypes (*in silico* and *de novo*) of 76 prioritized SNPs and 27 AIMs were available from 2,677 AN cases and 8,629 controls of European ethnicity and 458 AN cases and 421 controls from Japan.

Association analyses of prioritized SNPs were performed under an additive genetic model within each replication dataset with and without adjustment for AIMs. AIMs that showed nominally significant \( P \)-values for allele frequency differences between *de novo* typed cases and controls were used for conditional analysis (Table S3). As there were no qualitative differences between these results, the main text reports the unadjusted results. The USA replication dataset contained individuals who were related to individuals from the USA discovery dataset. As such, those samples were excluded from the discovery dataset and combined with replication USA samples to correctly account for relatedness between samples for the final global meta-analysis and sign test. Software packages GenABEL and
GEMMA\textsuperscript{55} were used for replication analysis of the USA dataset. Fixed-effects meta-analysis across the replication datasets was performed using GWAMA\textsuperscript{50} (with and without adjustment for AIMs and in samples of European ancestry only, i.e., excluding Japan, also with and without adjustment for AIMs). We also performed meta-analyses across the discovery and replication datasets, comprising a total of 5,551 AN cases and 21,080 controls (USA discovery samples were included only once as part of the replication phase). We calculated the power of the final global meta-analysis using QUANTO\textsuperscript{56}.

Seventy-two independent SNPs were used to compare the direction of effects between the discovery and replication meta-analyses using R\textsuperscript{57}. For this analysis, the USA samples were used only once as part of the replication meta-analysis.

### Additional analyses

We performed three additional analyses: 1) genome-wide complex trait analysis (GCTA), designed to estimate the proportion of phenotypic variance explained by genome-wide SNPs for complex traits\textsuperscript{58}, a network analysis, and a gene-based association test (Supplementary Information).

### AN subtype analyses

Two subtype (Supplementary Information) association analyses were performed for the 76 prioritized SNPs across the discovery and replication datasets (Table 1). In total, the AN restricting subtype global meta-analysis included 1,606 cases and the AN binge-purge subtype analysis included 1,445 cases. Both analyses used the same set of 16,303 controls (Supplementary Information).

### Related traits

Using the discovery meta-analysis, we investigated evidence for association using SNP results from published studies: 9 SNPs with nominal evidence of association with AN\textsuperscript{42}, 14 SNPs suggestively associated with eating disorder-related symptoms, behaviors, or personality traits\textsuperscript{59,60}, 89 SNPs with genome-wide significance in studies of BMI or obesity\textsuperscript{61,62}, and 15 SNPs related to morbid obesity\textsuperscript{61}. We also investigated evidence for association across the 72 replication SNPs using published GWAS results from the Psychiatric Genomics Consortium (https://pgc.unc.edu) for attention-deficit/hyperactivity disorder (ADHD), schizophrenia, bipolar disorder, and major depressive disorder\textsuperscript{63-66}.

### Expression studies

We prioritized the top 20 SNPs in terms of statistical significance and quantified the expression of the two nearest genes per SNP (Table S4) in 12 inbred strains of mice. We obtained publicly available RNAseq data from whole brain tissue samples and used standard software to map and count the sequence reads (Supplementary Information).
Results

Main association results

Of 1,185,559 imputed SNPs that passed QC, 287 showed evidence for association in the discovery stage with $P < 10^{-4}$. These variants represented 66 independent signals and had frequencies and effect sizes commensurate with observations in other common complex diseases. One variant, not surrounded by other SNPs achieving low p-values and for which genotypes were only available in two of the 15 initial study groups, surpassed genome-wide significance (rs4957798, $P=1.67\times10^{-12}$) but was not subsequently replicated in the global meta-analysis across discovery and replication samples. The overall $\lambda_{GC}$ was 1.03 (Figures S3 and S4). Seventy-six SNPs (of which 72 were independent) were prioritized for follow-up through *in silico* and *de novo* replication (Table S5). Nine SNPs showed association with $P < 0.05$ (minimum p-value was 0.003) in the replication dataset meta-analysis (binomial $P=0.0135$) (Table S5). Based on 72 independent SNPs taken forward, we would expect $0.05\times72=3.6$ SNPs to reach $P=0.05$ by chance. The 0.0135 $P$ value reflects this enrichment in signal. No signals surpassed genome-wide significance ($P=5\times10^{-8}$) in the final global meta-analysis across all discovery and replication samples (Table S5) or in the AN subtype analyses (Tables S6-S7).

Of critical importance, we observed significant evidence of SNP effect sizes in the replication data in the same direction as the discovery set (55/72 signals, sign test binomial $P=4\times10^{-6}$). This enrichment was also observed for the AN restricting (58/72, $P=8\times10^{-8}$) and binge-purge (56/72, $P=1\times10^{-6}$) subtype analyses. These results strongly indicate that the prioritized set of variants is likely to contain true positive signals for AN but that the current sample size is insufficient to detect these effects.

Our analysis revealed two notable variants: rs9839776 ($P=3.01\times10^{-7}$) in SOX2OT (SOX2 overlapping transcript) and rs17030795 ($P=5.84\times10^{-6}$) in PPP3CA (protein phosphatase 3, catalytic subunit, alpha isoform) (Table 2). Two additional signals emerged from the analysis focused on European replication samples only: rs1523921 ($P=5.76\times10^{-6}$) located between CUL3 (cullin 3) and FAM124B (family with sequence similarity 124B) and rs1886797 ($P=8.05\times10^{-6}$) located 18kb from SPATA13 (spermatogenesis associated 13) (Table S5). Four signals were in neurodevelopmental genes regulating synapse and neuronal network formation (SYN2, NCAM2, CNTNAP2 and CTNNA2; Table 2).

AN subtype analyses

In the AN restricting subtype analyses, the two most significant signals were rs1523921 (as in the main analysis, $P=8.39\times10^{-5}$) and rs10777211 (P=8.95×10^{-5}) located 333kb from ATP2B1 (ATPase, calcium transporting, plasma membrane 1), both detected in the European-only analysis (Table S6). The most significant result for AN binge-purge analysis was rs9839776 (as in the main analysis, $P=3.97\times10^{-4}$) in SOX2OT, also in Europeans only (Table S7). Overall, signals from the main AN case-control analysis display similar levels of association across both AN subtypes (Table S8).
Additional analyses

GCTA is technically challenging when synthesizing data across multiple strata with small individual sample sizes. When we applied it to our data we saw great variability in the estimates of variance and did not judge the results reliable. Results of the gene-based association test and network analysis are presented in their entirety in Supplemental Information and Figure S5, both of which were unremarkable.

Related traits

Nine out of the 11 previously reported variants suggestively associated with AN were found in our discovery meta-analysis, and six of these 9 SNPs had the same direction of effect as originally reported (P=0.508) (Table S9). Twelve out of 14 variants previously reported to be associated with eating disorder-related symptoms, behaviors, and personality traits were found in our discovery meta-analysis and 7 had the same direction of effect (P=0.774) (Table S10), with one SNP (inside RUFY1) having P<0.05 (binomial P=0.459). We did not find evidence for signal enrichment in the 60 independent SNPs found in the Psychiatric Genomics Consortium data for ADHD, schizophrenia, bipolar disorder, or major depressive disorder63-66 (Table S11).

When we compared 76 (53 independent) SNPs from the AN results with 89 established BMI/obesity SNPs, five SNPs (inside NEGR1, PTBP2, TMEM18, FTO and MC4R) had P<0.05 (binomial P=0.1906). Twenty-six of these 53 SNPs had the same direction of effect as originally reported (binomial P value=1) (Table S12). Thirteen of 15 SNPs associated with extreme obesity were extracted from our dataset and 9 of these were independent. Four of these 9 SNPs had the same direction of effect as originally reported (binomial P value=1) (Table S13). Three SNPs (in TMEM18, FTO and MC4R) had P<0.05 (binomial P value=0.0084), indicating modest enrichment of nominally associated SNPs from extreme obesity in our discovery dataset.

Expression studies

We analyzed RNAseq data for whole-brain tissue obtained from 12 different mouse strains(Figure 1). We performed this analysis for 32 mouse orthologues of the 34 human genes identified (Table S4). All 32 genes were expressed in the brain, above an average of 2 FPKM (Fragments Per Kilobase of exon per Million fragments mapped). Specifically, we find extremely high expression levels for Ppp3ca (FPKM value 36.40). Further, we find high expression for Sox2ot, with an FPKM value of 8.02, and similar expression values for Cul3 (10.01) and Ctnna2 (10.79).

Discussion

Given that the evidence base for the treatment of AN remains weak and that no effective medications for its treatment exist, advances in our understanding of the underlying biology of the disorder are essential in order to develop novel therapeutics and to reduce the loss of life and diminution of quality of life associated with the disorder. The GCAN/WTCCC3 investigation represents an unprecedented international genetic collaboration in the study of AN, which sets the foundation for further genetic studies.
Our final global meta-analysis had 80% power to detect SNPs with allele frequency of 0.35 and genotypic relative risk of 1.15 ($\alpha=5\times10^{-8}$, additive model). The AN subtype meta-analysis had 80% power to detect SNPs with allele frequency of 0.35 and genotypic relative risk 1.27 for the AN restricting subtype and 1.28 for the AN binge-purge subtype. Given these limitations in power, our strongest indicator that larger sample sizes could detect genetic variants associated with AN was revealed in the sign tests. The strong and significant evidence for SNP effect sizes in the same direction between discovery and replication sets ($P=4\times10^{-6}$) clearly suggests that larger sample sizes could successfully identify variants associated with AN and with the AN subtypes potentially enabling differentiation on a genetic level between restricting and binge/purge subtypes.

Several genetic variants were suggestively associated with AN ($P<10^{-5}$) (Table 2). Two variants, rs9839776 in SOX2OT and rs17030795 in PPP3CA, were identified through analysis of all discovery and replication datasets. Two additional variants with $P<10^{-5}$, rs1523921 located between CUL3 and FAM124B and rs1886797 located near SPATA13, were identified through analysis of individuals of European descent only (Table S5), suggesting either heterogeneity in the effects of these SNPs by ancestry or low power. The genes displayed in Table 2 are discussed in greater detail in the Supplementary Information; however, we highlight that four of these variants are neurodevelopmental genes that regulate synapse and neuronal network formation (SYN2, NCAM2, CNTNAP2 and CTNNA2) and two have been associated with Alzheimer's disease (SOX2OT and PPP3CA). Additionally, one of our prioritized SNPs (rs6558000) (Table S5) is located in close vicinity (9kb upstream) of the EPHX2 gene that was recently identified as a susceptibility locus to AN through candidate gene sequencing study of early-onset severe AN cases and controls.

Our expression studies further extend the GWAS findings. It is reasonable, although perhaps not essential, to expect that genes implicated in AN be expressed in the brain. Supporting this assumption, 32 mouse orthologues of 34 human genes identified as being of interest were expressed at least at a low level in mouse brain. Moreover, genes corresponding to the more strongly associated genetic variants tended to be more highly expressed. For example, high FPKM values for Ppp3ca, Cul3, and Sox2ot underscore that these genes may play a neuropsychiatric role.

AN subtype analyses were included to determine whether differences might exist between the classic restricting subtype of AN and the subtype marked by dysregulation characterized by binge eating and/or purging behavior. These analyses had lower power due to the smaller sample sizes. Only two SNPs, rs1523921 (also found to be suggestively associated in the main case-control analysis) and rs10777211 located 333kb upstream of ATP2B1, showed association at the $10^{-5}$ significance level (Table S6). Similarly, subsequent analyses pertaining to associated phenotypes (weight regulation: BMI/obesity loci, and loci for extreme obesity, psychiatric comorbidities: ADHD, schizophrenia, bipolar disorder, and major depressive disorder) or previous equivocal association findings for AN or eating disorders (AN variants, eating disorder related symptoms, behaviors, and personality traits variants) did not reveal significant findings. More adequately powered analyses that could allow us to detect variants that can distinguish between these two
subtypes could be clinically meaningful in predicting clinical course and outcome and eventually in designing targeted therapeutics.

Our understanding of the fundamental genetic architectures of complex medical diseases and psychiatric disorders has expanded rapidly.\textsuperscript{73} It has also become manifestly clear that genomic searches for common variation via GWAS can successfully uncover biological pathways of etiological relevance. The major limitation to discovery is sample size.\textsuperscript{74} A recent GWAS for schizophrenia reported the identification of 22 genome-wide significant loci for schizophrenia (21,000 cases and 38,000 controls), and the results yielded multiple themes of clear biological and translational significance (e.g., calcium biology and miR-137 regulation).\textsuperscript{75} Moreover, given that cases and controls were derived from multiple sources and genotyped on multiple platforms, imputation was essential. Although effective, the preferred approach will always be to have samples genotyped on the same platform to maximize comparability and the capacity to identify genomic associations.

Although the underlying biology of AN remains incompletely understood, the relative homogeneity of the phenotype, replicated heritability estimates, and encouraging results of the sign tests presented herein strongly encourage continuing this path of discovery. Phenotypic refinement and the identification of biomarkers of illness (independent of biomarkers of starvation) could assist with identification of risk loci. We believe that the surest and fastest path to fundamental etiological knowledge about the biological basis of AN is via GWAS in larger samples.\textsuperscript{74} This path is notably safe given that it relies on off-the-shelf technology whose utility has been proven in empirical results for multiple biomedical and psychiatric disorders. This approach is cost-effective due to recent sharp decreases in genotyping pricing. Therefore, we believe that accrual of large genotyped AN case-control samples should be an immediate priority for the field.

**Supplementary Material**

Refer to Web version on PubMed Central for supplementary material.

**Authors**

Vesna Boraska, PhD\textsuperscript{1,2,*}, Christopher S Franklin, PhD\textsuperscript{1,*}, James AB Floyd, PhD\textsuperscript{1,3,*}, Laura M Thornton, PhD\textsuperscript{4,*}, Laura M Huckins\textsuperscript{1}, Lorraine Southam, BSc\textsuperscript{1}, N William Rayner, PhD\textsuperscript{1,5,6}, Ioanna Tachmazidou, PhD\textsuperscript{1}, Kelly L Klump, PhD\textsuperscript{7}, Janet Treasure, PhD, FRCP, FRCPsych\textsuperscript{8}, Cathryn M Lewis, PhD\textsuperscript{8}, Ulrike Schmidt, MD, PhD, FRCpsych\textsuperscript{8}, Federica Tozzi, MD\textsuperscript{4}, Kirsty Kiezebrink, PhD, RNutr\textsuperscript{10}, Johannes Hebebrand, MD\textsuperscript{11}, Philip Gorwood, MD, PhD\textsuperscript{12,13}, Roger AH Adan, PhD\textsuperscript{14,15}, Martien JH Kas, PhD\textsuperscript{14}, Angela Favaro, MD, PhD\textsuperscript{16}, Paolo Santonastaso, MD\textsuperscript{16}, Fernando Fernández-Aranda, PhD\textsuperscript{17,18}, Monica Gratacos, MD, PhD\textsuperscript{19,20,21,22}, Filip Rybakowski, MD, PhD\textsuperscript{23}, Monika Dmitrzak-Weglarz, PhD\textsuperscript{24}, Jaakko Kaprio, MD, PhD\textsuperscript{25,26,27}, Anna Keski-Rahkonen, MD, PhD, MPH\textsuperscript{25}, Anu Raevuori, MD, PhD\textsuperscript{25,28}, Eric F Van Furth, PhD\textsuperscript{29,30}, Margarita CT Slof-Op t Landt, PhD\textsuperscript{29,31}, James I Hudson, MD, ScD\textsuperscript{32}, Ted Reichborn-Kjennerud, MD, PhD\textsuperscript{33,34}, Gun Peggy S Knudsen, PhD\textsuperscript{33}, Palmiero Monteleone, MD\textsuperscript{35,36}, Allan S Kaplan, MD, MSc,
FRCP(C)37,38, Andreas Karwautz, MD39, Hakon Hakonarson, MD, PhD40,41, Wade H Berrettini, MD, PhD42, Yiran Guo, PhD40, Dong Li, PhD40, Nicholas J. Schork, PhD43, Gen Komaki, MD, Ph.D44,45, Tetsuya Ando, MD, PhD44, Hidetoshi Inoko, PhD46, Tönu Esko, PhD47, Krista Fischer, PhD47, Katrin Männik, PhD48,49, Andres Metspalu, MD, PhD47,48, Jessica H Baker, PhD4, Roger D Cone, PhD50, Jennifer Dackor, PhD51, Janiece E DeSocio, PhD, RN, PMHNP-BC52, Christopher E Hilliard, BS4, Julie K O’Toole, MD, MPH53, Jacques Pantel, PhD54, Jin P Szatkinskiewicz, PhD51, Chrysecolla Taico, MSW, LCSW4, Stephanie Zerwas, PhD4, Sara E Trace, PhD4, Oliver SP Davis, Ph.D9,55, Sietske Helder, PhD9, Katharina Bühren, MD56, Roland Burghardt, MD57, Martina de Zwaan, MD58,59, Karin Egberts, MD60, Stefan Ehrich, MD61,62, Beate Herpertz-Dahlmann, MD56, Wolfgang Herzog, MD63, Hartmut Imgart, MD64, André Scherag, Ph.D65, Susann Scherag, Ph.D11, Stephan Zipfel, MD66, Claudette Boni, PhD12, Nicolas Ramoz, PhD12, Audrey Versini, Ph.D12, Marek K Brandys, MSc14,15, Unna N Danner, Ph.D15, Carolien de Kovel, Ph.D67, Judith Hendriks14, Bobby PC Koeleman, PhD67, Roel A Ophoff, PhD68,69, Eric Strengman, MSc67, Annemarie A van Elburg, MD, PhD15,70, Alice Bruson, Ph.D71, Maurizio Clementi, MD71, Daniela Degortes, Ph.D16, Monica Forzan, Ph.D71, Elena Tenconi, Ph.D16, Elisa Docampo, MD, PhD19,20,21,22, Georgiá Escaramís, Ph.D19,20,21,22, Susana Jiménez-Murcia, PhD17,18, Jolanta Lissowska, PhD72, Andrzej Rajewski, MD, PhD73, Neoniла Szeszenia-Dabrowska, MD, Ph.D73, Agnieszka Słopień, MD, PhD24, Joanna Hauser, MD, Ph.D24, Leila Karhunen, Ph.D74, Ingrid Meulenberg, Ph.D31, P Eline Slagboom, Ph.D31,75, Alfonso Tortorella, MD35, Mario Maj, MD, PhD35, George Dedoussis, Ph.D76, Dimitris Dikeos, MD77, Fragiskos Goniakis, MD78, Konstantinos Tziouvas, MD, MSc76, Artemis Tsitsika, MD, Ph.D79, Hana Papezova, MD, Ph.D80, Lenka Slachtova, MSc81, Debora Martaskova, MSc80, James L. Kennedy, MD, MSc, FRCP(C)37,38, Robert D. Levitan, MD, MSc, FRCP(C)37,38, Zeynep Yilmaz, Ph.D4,37, Julia Huemer, MD39, Doris Koubek, MD39, Elisabeth Merl, MD39, Gudrun Wagner, MSc, Dr med sci39, Paul Lichtenstein, Ph.D82, Gerome Breen, Ph.D9, Sarah Cohen-Woods, Ph.D9, Anne Farmer, MD, FRCPsych9, Peter McGuffin, MD, Ph.D9, Sven Cichon, Ph.D83,84,85, Ina Giegling, Ph.D86, Stefan Herms, Ph.D83,85, Dan Rujescu, MD, Ph.D86, Stefan Schreiber, MD87, H-Erich Wichmann, MD88,89, Christian Dina, Ph.D90, Rob Sladek, MD91, Giovanni Gambaro, MD, Ph.D92, Nicole Soranzo, Ph.D1, Antonio Julia, MD93, Sara Marsal, MD, Ph.D93, Raquel Rabionet, Ph.D19,22, Valerie Gaborieau, MS94, Danielle M Dick, Ph.D95, Arno Palotie, MD, Ph.D1,96,97, Samuli Ripatti, Ph.D96,98, Elisabeth Widén, MD, Ph.D96,98, Ole A Andreassen, MD, Ph.D99, Thomas Epseseth, Ph.D99,100, Astrid Lundervold, Ph.D101,102,103, Ivar Reinvang, Ph.D100, Vidar M Steen, MD, Ph.D104,105, Stephanie Le Hellard, Ph.D104,105, Morten Mattingsdal, MSc99, Ioanna Ntalía, Ph.D76, Vladimir Bencko, MD106, Lenka Foretova, MD, Ph.D107, Vladimir Janout, MD108, Marie Navratilova, MD, Ph.D107, Steven Gallinger, MD, MSc, FRCS109, Dalila Pinto, Ph.D110, Stephen Scherer, Ph.D111, Harald Aschauer, MD112, Laura Carlberg, MD112, Alexandra Schosser, MD, Ph.D112, Lars Alfredsson, Ph.D113, Bo Ding, Ph.D113, Lars Klæreskog, MD, Ph.D114, Leonid Padyukov, MD, Ph.D114, Chris Finan, Ph.D1, Gursharan Kalsi, Ph.D9, Marion Roberts, Ph.D9, Darren W Logan, Ph.D1, Leena Peltonen, Ph.D1, Graham RS Ritchie, Ph.D1,115, Jeffrey C

Mol Psychiatry. Author manuscript; available in PMC 2015 February 12.
Barrett, PhD\textsuperscript{1}, The Wellcome Trust Case Control Consortium 3, Xavier Estivill, MD, PhD\textsuperscript{19,20,21,22,**}, Anke Hinney, PhD\textsuperscript{11,**}, Patrick F Sullivan, MD, FRANZCP\textsuperscript{4,51,+}, David A Collier, PhD\textsuperscript{9,116,+}, Eleftheria Zeggini, PhD\textsuperscript{1,+}, and Cynthia M Bulik, PhD\textsuperscript{4,117,+}

**Affiliations**

\textsuperscript{1}Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK \textsuperscript{2}University of Split School of Medicine, Split, Croatia \textsuperscript{3}William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London, UK \textsuperscript{4}Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA \textsuperscript{5}Wellcome Trust Centre for Human Genetics (WTCHG), University of Oxford, Oxford, UK \textsuperscript{6}Oxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM), Oxford, UK \textsuperscript{7}Department of Psychology, Michigan State University, East Lansing, MI, USA \textsuperscript{8}Section of Eating Disorders, Institute of Psychiatry, King's College London, London, UK \textsuperscript{9}Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, King's College London, London, UK \textsuperscript{10}Health Services Research Unit, University of Aberdeen, Aberdeen, UK \textsuperscript{11}Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Universitätsklinikum Essen, University of Duisburg-Essen, Essen, Germany \textsuperscript{12}INSERM U894, Centre of Psychiatry and Neuroscience, Paris, France \textsuperscript{13}Sainte-Anne Hospital (CMME), University of Paris-Descartes, Paris, France \textsuperscript{14}Brain Center Rudolf Magnus, Department of Neuroscience and Pharmacology, University Medical Center Utrecht, Utrecht, The Netherlands \textsuperscript{15}Altrecht Eating Disorders Rintveld, Zeist, The Netherlands \textsuperscript{16}Department of Neurosciences, University of Padova, Padova, Italy \textsuperscript{17}Department of Psychiatry and CIBERON, University Hospital of Bellvitge-IDIBELL, Barcelona, Spain \textsuperscript{18}Department of Clinical Sciences, School of Medicine, University of Barcelona, Barcelona, Spain \textsuperscript{19}Genomics and Disease Group, Centre for Genomic Regulation (CRG), Barcelona, Spain \textsuperscript{20}Universitat Pompeu Fabra (UPF), Barcelona, Spain \textsuperscript{21}Centro de Investigación Biomédica en Red en Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain \textsuperscript{22}Hospital del Mar Medical Research Institute (IMIM), 08003, Barcelona, Catalonia, Spain \textsuperscript{23}Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Neurology, Warsaw, Poland \textsuperscript{24}Department of Child and Adolescent Psychiatry, Department of Psychiatry, Poznan University of Medical Sciences, Poznan, Poland \textsuperscript{25}Hjelt Institute, University of Helsinki, Helsinki, Finland \textsuperscript{26}Institute of Molecular Medicine, University of Helsinki, Helsinki, Finland \textsuperscript{27}Department of Mental Health and Substance Abuse Services, National Institute for Health and Welfare, Helsinki, Finland \textsuperscript{28}Department of Adolescent Psychiatry, Helsinki University Central Hospital, Helsinki, Finland \textsuperscript{29}Center for Eating Disorders Ursula, Leidschendam, The Netherlands \textsuperscript{30}Leiden University Medical Centre, Department of Psychiatry, Leiden, The Netherlands \textsuperscript{31}Leiden University Medical Centre, Molecular Epidemiology Section (Department of Medical Statistics), Leiden, The Netherlands \textsuperscript{32}Department of Psychiatry, McLean Hospital/Harvard Medical School, Belmont, MA, USA \textsuperscript{33}Department of Genetics, Environment and Mental

\textit{Mol Psychiatry}. Author manuscript; available in PMC 2015 February 12.
Health, Norwegian Institute of Public Health, Oslo, Norway

34 Institute of Clinical Medicine, University of Oslo, Oslo, Norway

35 Department of Psychiatry, University of Naples SUN, Naples, Italy

36 Chair of Psychiatry, University of Salerno, Salerno, Italy

37 Centre for Addiction and Mental Health, University of Toronto, Toronto, Canada

38 Department of Psychiatry, University of Toronto, Toronto, Canada

39 Eating Disorders Unit, Department of Child and Adolescent Psychiatry, Medical University of Vienna, Vienna, Austria

40 The Center for Applied Genomics, The Children’s Hospital of Philadelphia, Philadelphia, PA, USA

41 The Division of Human Genetics, Department of Pediatrics, The Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

42 Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA

43 Department of Molecular and Experimental Medicine and The Scripps Translational Science Institute, The Scripps Research Institute, La Jolla, CA, USA

44 Department of Psychosomatic Research, National Institute of Mental Health, NCNP, Tokyo, Japan

45 School of Health Sciences at Fukuoka, International University of Health and Welfare, Fukuoka, Japan

46 Department of Molecular Life Sciences, Tokai University School of Medicine, Kanagawa, Japan

47 Estonian Genome Center, University of Tartu, Tartu, Estonia

48 Institute of Molecular and Cell Biology, University of Tartu, Tartu, Estonia

49 Center for Integrative Genomics, University of Lausanne, Lausanne, Switzerland

50 Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, TN, USA

51 Department of Genetics, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

52 Seattle University College of Nursing, Seattle, WA, USA

53 Kartini Clinic, Portland, OR, USA

54 Centre de Psychiatrie et Neurosciences - Inserm U894, Paris, France

55 UCL Genetics Institute, Department of Genetics, Evolution and Environment, University College London, London, UK

56 Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Clinics RWTH Aachen, Aachen, Germany

57 Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Charité, Berlin, Germany

58 Department of Psychosomatic Medicine and Psychotherapy, Hannover Medical School, Hannover, Germany

59 Department of Psychosomatic Medicine and Psychotherapy, University of Erlangen-Nuremberg, Erlangen, Germany

60 Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Würzburg, Würzburg, Germany

61 Department of Child and Adolescent Psychiatry, University Hospital Carl Gustav Carus, Dresden University of Technology, Dresden, Germany

62 Massachusetts General Hospital/Harvard Medical School, Athinoula A. Martinos Center for Biomedical Imaging, Psychiatric Neuroimaging Research Program, Charlestown, MA, USA

63 Departments of Psychosocial and Internal Medicine, Heidelberg University, Heidelberg, Germany

64 Parklandklinik, Bad Wildungen, Germany

65 Institute for Medical Informatics, Biometry and Epidemiology, Universitätsklinikum Essen, University of Duisburg-Essen, Essen, Germany

66 Department of Internal Medicine VI, Psychosomatic Medicine and Psychotherapy, University Medical Hospital Tübingen, Tübingen, Germany

67 Department of Medical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands

Mol Psychiatry. Author manuscript; available in PMC 2015 February 12.
Neurobehavioral Genetics, University of California, Los Angeles, Los Angeles, CA, USA
Brain Center Rudolf Magnus, Department of Psychiatry, University Medical Center Utrecht, The Netherlands
Department of Child and Adolescent Psychiatry, University Medical Center Utrecht, Utrecht, The Netherlands
Clinical Genetics Unit, Department of Woman and Child Health, University of Padova, Padova, Italy
M. Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland
Department of Epidemiology, Institute of Occupational Medicine, Department of Epidemiology, Lodz, Poland
Department of Clinical Nutrition, Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland
Netherlands Consortium for Healthy Ageing, Leiden University Medical Center, The Netherlands
Department of Nutrition and Dietetics, Harokopio University, Athens, Greece
1st Department of Psychiatry, Athens University Medical School, Athens, Greece
Eating Disorders Unit, 1st Department of Psychiatry, Athens University Medical School, Athens, Greece
Adolescent Health Unit (A.H.U.), 2nd Department of Pediatrics – Medical School, University of Athens “P. & A. Kyriakou” Children’s Hospital, Athens, Greece
Department of Psychiatry, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
Department of Pediatrics, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
Institute of Human Genetics, Department of Genomics, Life & Brain Center, University of Bonn, Bonn, Germany
Institute of Neuroscience and Medicine (INM-1), Research Center Jülich, Jülich, Germany
Division of Medical Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland
Martin-Luther-Universität Halle-Wittenberg, Klinikum der Medizinischen Fakultät, Halle/Saale, Germany
Institute of Clinical Molecular Biology, University of Kiel, Germany
Institute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany
Institute of Medical Informatics, Biometry and Epidemiology, Ludwig-Maximilians-University, Munich, Germany
CNRS 8090-Institute of Biology, Pasteur Institute, Lille, France
McGill University and Genome Quebec Innovation Centre, Montreal, Canada
Division of Nephrology, Department of Internal Medicine and Medical Specialties, Columbus-Gemelley Hospitals, Catholic University, Rome, Italy
Unitat de Recerca de Reumatologia (URR), Institut de Recerca Hospital Universitari Vall d'Hebron, Barcelona, Spain
Genetic Epidemiology Group, International Agency for Research on Cancer (IARC), Lyon, France
Virginia Institute for Psychiatric and Behavioral Genetics, Department of Psychiatry, Virginia Commonwealth University, VA, USA
The Finnish Institute of Molecular Medicine Finland (FIMM), University of Helsinki, Finland
The Program for Human and Population Genetics, The Broad Institute of MIT and Harvard, Cambridge, MA, USA
Finnish Institute of Occupational Health, Helsinki, Province of Southern Finland, Finland
NORMENT, K.G. Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital & Institute of Clinical Medicine, University of Oslo, Oslo, Norway
Department of Psychology, University of Oslo, Norway
Department of Biological and Medical Psychology, University of Bergen, Norway
Kavli Research Center, University of Oslo, Norway

Mol Psychiatry. Author manuscript; available in PMC 2015 February 12.
Acknowledgments

Acknowledgment for Funding, Biomaterials, and Clinical Data

Wellcome Trust Sanger Institute The WTCCC3

This work was funded by a grant from the WTCCC3 WT088827/Z/09 entitled “A genomewide association study of anorexia nervosa.”

Data Analysis Group: Carl A. Anderson1, Jeffrey C. Barrett1, James A.B. Floyd1, Christopher S. Franklin1, Ralph McGinnis1, Nicole Soranzo1, Eleftheria Zeggini1.


Management Committee: Graeme Alexander5, Cynthia M. Bulik6, David A. Collier7, Peter J. Conlon8, Anna Dominiczak9, Audrey Duncanson10, Adrian Hill11, Cordelia Langford1, Graham Lourd12, Alexander P. Maxwell13, Linda Morgan14, Leena Peltonen1, Richard N. Sandford15, Neil Sheerin12, Nicole Soranzo1, Fredrik O. Vannberg11, Jeffrey C. Barrett1 (chair).

DNA, Genotyping, and Informatics Group: Hannah Blackburn1, Wei-Min Chen16, Sarah Edkins1, Mathew Gillman1, Emma Gray1, Sarah E. Hunt1, Cordelia Langford1, Suna Onengut-Gumuscu16, Simon Potter1, Stephen S Rich16, Douglas Simpkin1, Pamela Whittaker1.

1. The Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK
2. Division of Transfusion Medicine, Department of Haematology, University of Cambridge, NHSBT Cambridge Centre, Long Road, Cambridge, CB2 0PT, UK
3. Department of Social Medicine, University of Bristol, Bristol BS8 2BN, UK
4. St. George's University, Division of Community Health Sciences, London SW19 0RE, UK
5. Department of Hepatology, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK
6. Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
7. Institute of Psychiatry, King's College London, London SE5 8AF
8. Department of Nephrology, Beaumont Hospital, Dublin, Ireland and Royal College of Surgeons Dublin, Ireland
9. BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow G12 8TA, UK
10. Gibbs Building, 215 Euston Road, London NW1 2BE, UK
11. Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX1 2JF, UK
12. MRC Centre for Transplantation, King's College London, London SE1 9RT, UK
13. Belfast City Hospital, Lisburn Road, Belfast BT9 7AB, UK
14. School of Molecular Medical Sciences, University of Nottingham, Nottingham NG7 2UH, UK
15. Academic Department of Medical Genetics, Cambridge University, Cambridge CB2 0QQ, UK
16. Center for Public Health Genomics, University of Virginia, Charlottesville, VA, USA

Additional Wellcome Trust Acknowledgements
1. This work was supported by the Wellcome Trust (098051).
2. Eleftheria Zeggini is supported by the Wellcome Trust (098051).
3. Vesna Boraska is supported by Unity Through Knowledge Fund CONNECTIVITY PROGRAM (“Gaining Experience” Grant 2A), The National Foundation for Science, Higher Education and Technological Development of the Republic of Croatia (BRAIN GAIN- Postdoc fellowship) and the Wellcome Trust (098051).
4. Christopher S Franklin is supported by the WTCCC3 project, which is supported by the Wellcome Trust (WT090355/A/09/Z, WT090355/B/09/Z).
5. James A B Floyd is supported by the WTCCC3 project, which is supported by the Wellcome Trust (WT090355/A/09/Z, WT090355/B/09/Z).
6. Lorraine Southam is supported by the Wellcome Trust (098051).
7. William N Rayner is supported by the Wellcome Trust (098051).
8. The Wellcome Trust Case Control Consortium 3 project is supported by the Wellcome Trust (WT090355/A/09/Z, WT090355/B/09/Z).
9. We acknowledge use of data from the British 1958 Birth Cohort and the UK National Blood Service.
10. We obtained High Density SNP Association Analysis of Melanoma: Case-Control and Outcomes Investigation dataset through dbGaP (dbGaP Study Accession: phs000187.v1.p1). Research support to collect data and develop an application to support this project was provided by 3P50CA093459, SP50CA097007, 5R01ES011740, and 5R01CA133996.
11. Laura Huckins acknowledges Wellcome Trust (098051) and the MRC (MR/J500355/1) and Ximena Ibarra-Soria for advice on RNA-seq analysis.

Austria. Medical University of Vienna. The study was partly supported by the European Commission, Framework 5 research program, Integrated Project QLK1-CT-1999-00916 “Factors in Healthy Eating” given to the consortium lead by Prof. J. Treasure and Prof. D. Collier, London. We thank Gerald Nobis, Dr. Maria Haidvogl, and Dr. Julia Philipp for help with data collection and interview work.

Canada. Canadian Institutes of Health Research (CIHR). Zeynep Yilmaz was supported by a CIHR Doctoral Research Award (Genetic Determinants of Low Body Weight in Anorexia Nervosa; funding reference: GSD-111968). The Toronto authors would like to thank Sajid Shaikh, Maria Tampakeras, and Natalie Freeman for DNA preparation and laboratory support.

Mol Psychiatry. Author manuscript; available in PMC 2015 February 12.
Canada. The Ontario Mental Health Foundation (OMHF). The collection of the Toronto DNA samples was supported by a grant from the OMHF, awarded to Allan S. Kaplan and Robert D. Levitan (Polymorphism in Serotonin System Genes: Putative Role in Increased Eating Behaviour in Seasonal Affective Disorder and Bulimia Nervosa).

Czech Republic. Charles University. The study was supported by grants IGA MZ ČR NS/10045-4 and IGA NT 14094/5 from the Czech Ministry of Education and Health and PRVOUK P24/LF1/3 and P26/LF1/4 Charles University, Prague, and from the Marie Curie Research Training Network INTACT (MRTN-CT-2006-035988).

Finland. University of Helsinki, Academy of Finland Center of Excellence in Complex Disease Genetics (grant numbers: 213506, 129680), ENGAGE – European Network for Genetic and Genomic Epidemiology, FP7-HEALTH-F4-2007, grant agreement number 20143. Data collection in the Finnish Twin studies has been supported by the National Institute of Alcohol Abuse and Alcoholism (grants AA-12502, AA-00145, and AA-09203 to R J Rose and AA15416 and K02A018755 to D M Dick), the Academy of Finland (grants 100499, 205585, 118555 and 141054, 265240, and 264146 to JK). AR and LK were supported by the Academy of Finland, grants 259764 and 28327, respectively.

France. Institut National de la Santé et de la Recherche Médicale (INSERM), France. This French cohort was recruited with grants from EC Framework V ‘Factors in Healthy Eating’ (a consortium coordinated by Janet Treasure and David Collier, King's College London), and from INRA/INSERM (4M406D), and the participation of Audrey Versini's work was supported by grants from ‘Région Ile-de-France’. Cases were ascertained from Sainte-Anne Hospital (Paris) and Robert Debre Hospital (Paris).

Genetics of Anorexia Nervosa (GAN). National Institute of Mental Health. The data and collection of biomaterials for the GAN study have been supported by the National Institutes of Health Grants (MH066122, MH066117, MH066145, MH066296, MH066147, MH0662, MH066193, MH066287, MH066288, MH066146). The principal investigators and co-investigators of this study were: University of Pittsburgh, Pittsburgh, PA: Walter Kaye, M.D., Bernie Devlin, Ph.D.; University of North Carolina at Chapel Hill, Chapel Hill, NC: Cynthia M Bulik, Ph.D.; Roseneck Hospital for Behavioral Medicine, Prien and Department of Psychiatry, University of Munich, Germany: Manfred M Fichter, M.D.; Kings College London, Institute of Psychiatry, London, UK: Janet Treasure, M.D.; Toronto General Hospital, Toronto, Ontario, Canada: Allan Kaplan, M.D., D. Blake Woodside, M.D.; Laureate Psychiatric Hospital, Tulsa, OK: Craig L. Johnson, Ph.D.; Weill Cornell Medical College, White Plains, NY: Katherine Halmi, M.D.; Sheppard Pratt Health System, Towson, MD: Harry A. Brandt, M.D., Steve Crawford, M.D.; Neuropsychiatric Research Institute, Fargo, ND; James E. Mitchell, M.D.; University of California at Los Angeles, Los Angeles, CA: Michael Strober, Ph.D.; University of Pennsylvania, Philadelphia, PA: Wade Berrettini, M.D., Ph.D.; and University of Birmingham, England: Ian Jones, M.D. We are indebted to the participating families for their contribution of time and effort in support of this study. The authors also wish to thank the Price Foundation for sponsoring the earlier work of this collaboration and would like to thank the study managers and clinical interviewers for their efforts in participant screening and clinical assessments.

Germany. University of Duisburg-Essen. Sample collection was funded by grants from the German Federal Ministry of Education and Research (BMBF; EDNET 01GV0602, 01GV0624, 01GV0623 and 01GV0905, NGFPlus: 01GS0820) and the IFORES program of the University of Duisburg-Essen. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Germany. Prof. Ehrlich's work is supported by DFG grant HE 367/5-1 and the SFB 940.

GlaxoSmithKline (GSK), Leeds (Yorkshire Centre for Eating Disorders). The authors acknowledge the support of the Medical Research Council and GlaxoSmithKline for providing financial support of this project. The support of the Carnegie Trust in the form of a travel award is also acknowledged. We also acknowledge the help and support of the Discovery and Pipeline Genetics, and Translational Medicine and Genetics departments at GSK for their contributions to this study. In particular we would like to acknowledge Mike Stubbins, Julia Perry, Sarah Bujac, David Campbell (at GSK currently or at the time when the study was performed), John Blundell (Leeds University), and E Evleen Mann (Yorkshire Centre for Eating Disorders), for their fundamental contribution to the realization of this study.

Greece. Eating Disorders Unit, 1st Department of Psychiatry, Athens University, Medical School. Special thanks goes to Associate Professor Varsou E, Head of Eating Disorders Unit, and Professor Papadimitriou G, Chairman and Director of 1st Department of Psychiatry, Athens University, Medical School, for their advice and support.

Italy. Padua (BIOVEDA). BIOVEDA was funded thanks to a Grant of Veneto Region in 2009. Samples were collected at Padua, Verona, Treviso, Vicenza and Portogruaro hospitals.

Netherlands. Department of Neuroscience and Pharmacology, The Rudolf Magnus Institute of Neuroscience, University Medical Center, Utrecht and Rintveld, Center for Eating Disorders, Altrecht in Zeist. Marek K. Brandys was supported by funding from the Marie Curie Research Training Network INTACT (Individually tailored stepped
care for women with eating disorders; reference number: MRTN-CT-2006-035988). Martien Kas was supported by a ZonMW VIDI-grant (91786327) from The Netherlands Organization for Scientific Research (NWO).

Norway. The National Institute of Public Health Twin Panel (NIPHTP). The NIPHTP was supported in part by grants from The Norwegian Research Council, The Norwegian Foundation for Health and Rehabilitation, The Norwegian Council for Mental Health and The European Commission under the program ‘Quality of Life and Management of the Living Resources’ of 5th Framework Program (no. QLG2-CT-2002-01254).

Poland. Poznan University of Medical Sciences (PUMS). PUMS study was sponsored by KBN scientific grant no. POSB 12823

Spain. Department of Psychiatry University Hospital of Bellvitge-IDIBELL, Barcelona. Financial support was received from Fondo de Investigación Sanitaria -FIS (PI11/210) and AGAUR (2009SGR1554). CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn) is an initiative of ISCIII.

Sweden. Karolinska Institutet, Stockholm. The Swedish Twin Registry is supported by the Swedish Department of Higher Education. The STR was supported by grants from the Ministry for Higher Education, the Swedish Research Council (M-2005-1112 and 2009-2298), GenomEUtwin (EU/QLRT-2001-01254; QLG2-CT-2002-01254), NIH grant DK U01-066134, The Swedish Foundation for Strategic Research (SSF; ICA08-0047), the Swedish Heart-Lung Foundation, the Royal Swedish Academy of Science, and ENGAGE (within the European Union Seventh Framework Programme, HEALTH-F4-2007-201413).

United Kingdom. King’s College London. Financial support was received from the European Union (Framework-V Multicentre Research Grant, QLK1–1999-916), a Multicentre EU Marie Curie Research Training Network grant, INTACT (MRTN-CT-2006-035988) and a Marie-Curie Intra-European Fellowship (FP-7-People-2009-IEF, No. 254774). Dr. Oliver Davis is supported by a Sir Henry Wellcome Fellowship from the Wellcome Trust (WT088984). Cathryn Lewis is partly supported by the National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health at South London and Maudsley NHS Foundation Trust and Institute of Psychiatry, King’s College London.

United States. McLean Hospital/Harvard Medical School, Cambridge, MA. The collection of DNA from participants at the McLean Hospital/Harvard Medical School site was supported in part by an investigator-initiated grant from Ortho-McNeil Janssen Scientific Affairs (principal investigator: Dr. Hudson).

United States. University of North Carolina. Sample collection was funded by a grant from the Foundation of Hope, Raleigh, North Carolina. Sara Trace, PhD, Jin Szatkiewicz, PhD, and Jessica Baker, PhD were funded by T32 MH076694 (PI:Buik). Sara Trace was funded by a 2012–2015 Hilda and Preston Davis Foundation Postdoctoral Fellowship Program in Eating Disorders Research Award. Stephanie Zerwas, PhD was funded by a UNC BIRWCH award K12HD001441. The Clinical and Translational Science Award (CTSA) program at UNC-Chapel Hill provided additional assistance UL1TR000083.

United States. Vanderbilt University School of Medicine, Nashville TN, and the Kartini Clinic for Disordered Eating, Portland, OR. Cases were ascertained from the Kartini Clinic, Portland Oregon. Sample collection and processing was funded by a Bristol-Myers Squibb Freedom to Discover Unrestricted Metabolic Diseases Research Grant to RDC.

Replication Samples

Children’s Hospital of Philadelphia/Price Foundation. We gratefully thank all the patients and their families who were enrolled in this study, as well as all the control subjects who donated blood samples to Children’s Hospital of Philadelphia (CHOP) for genetic research purposes. We thank the Price Foundation for their support of the Collaborative Group effort that was responsible for recruitment of patients, collection of clinical information and provision of the DNA samples used in this study. The authors also thank the Klarman Family Foundation for supporting the study. We thank the technical staff at the Center for Applied Genomics at CHOP for producing the genotypes used for analyses and the nursing, medical assistant and medical staff for their invaluable help with sample collections. CTB and NJS are funded in part by the Scripps Translational Sciences Institute Clinical Translational Science Award [Grant Number U54 RR025224-01J]. All genome-wide genotyping was funded by an Institute Development Award to the Center for Applied Genomics from the CHOP. 2011 - 2014 Davis Foundation Postdoctoral Fellowship Program in Eating Disorders Research Award, Yiran Guo, PhD; 2012 - 2015 Davis Foundation Postdoctoral Fellowship Program in Eating Disorders Research Award, Dong Li, PhD.

Estonia. Estonian Genome Center of the University of Tartu (EGCUT). EGCUT received targeted funding from Estonian Government SP018014208, Center of Excellence in Genomics (EXCEGEN) and University of Tartu (SP1GVARENG). We acknowledge EGCUT technical personnel, especially Mr. V. Soo and S. Smit. Data analyzes were carried out in part in the High Performance Computing Center of University of Tartu.

Mol Psychiatry. Author manuscript; available in PMC 2015 February 12.
Japan. National Institute of Mental Health, National Center of Neurology and Psychiatry. The data and sample collection have been supported by Grants-in-Aid for Scientific Research 20390201 and 23390201 to G. Komaki from the Ministry of Education, Culture, Sports, Science, and Technology, Japan. We are indebted to the members of the Japanese Genetic Research Group For Eating Disorders for their contribution of time and effort in collecting samples and clinical data.


Acknowledgements for Controls

Austria. Controls in Vienna were collected with support to Harald Aschauer by Österreichische Nationalbank (ÖNB Project Nr. 5777 and 13198), Austrian Science Fund (Pr. Nr. P7639), European Science Foundation (ESF Programme MMNI) and European Commission (Biomed 1, JI182E25A).

Canada. NIH grant No. - U24 CA074783 to S. Gallinger. This work was made possible through collaboration and cooperative agreements with the Colon Cancer Family Registry and PIs. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating institutions or investigators in the Colon CFR, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government or the Colon CFR.

Czech Republic. Support came from the European Regional Development Fund and the State Budget of the Czech Republic (RECAMO, CZ.1.05/2.1.00/03.0101).

dbGAP DAC. Research support to collect data and develop an application to support this project was provided by 3P50CA093459, 5P50CA097007, S01ES011740, and S01CA133996.

Germany. We thank all probands from the community-based cohorts of PopGen, KORA, and the Heinz Nixdorf Recall (HNR) study. This study was supported by the German Federal Ministry of Education and Research (BMBF), within the context of the National Genome Research Network plus (NGPplus), and the Mood-Net (grant 01GS08144 to S.C.). The KORA research platform was initiated and financed by the Helmholtz Center Munich, German Research Center for Environmental Health, which is funded by the BMBF and by the State of Bavaria. The Heinz Nixdorf Recall cohort was established with the support of the Heinz Nixdorf Foundation.

Greece. This research has been co-financed by the European Union (European Social Fund – ESF) and Greek national funds through the Operational Program “Education and Lifelong Learning” of the National Strategic Reference Framework (NSRF) - Research Funding Program: Heracleitus II. Investing in knowledge society through the European Social Fund.

Italy (North). Verona. The INCIFE study was co-sponsored by Fondazione Cassa di Risparmio di Verona, Azienda Ospedaliera di Verona, and University of Verona. Samples were collected in Verona, Padua, Monselice and Dolo. Co-principal investigators were Antonio Lupo and Giovanni Gambaro.

Netherlands. Genotyping of controls was funded by NIH/NIMH R01 MH078075, granted to Roel Ophoff.

Spain. Spanish Plan Nacional SAF2008-00357 (NOVADIS); the Generalitat de Catalunya AGAUR 2009 SGR-1502; the Instituto de Salud Carlos III (FIS/FEDER PI11/00733); and the European Commission 7th Framework Program, Project N. 261123 (GEUVADIS), and Project N. 262055 (ESGI).

References


Mol Psychiatry. Author manuscript; available in PMC 2015 February 12.
Figure 1.
Analysis of RNAseq data for whole-brain tissue obtained from 12 different mouse strains for 32 mouse orthologues of the 34 human genes for which association to anorexia nervosa (AN) was identified. The average FPKM (Fragments Per Kilobase of exon per Million fragments mapped) values for 32 genes across 12 mouse strains are shown.
Table 1
List of ethnicities and numbers of samples for main case control and anorexia nervosa (AN) subtype analyses across discovery and replication datasets

<table>
<thead>
<tr>
<th>Country</th>
<th>Cases (% of females)</th>
<th>AN RESTRICTING subtype cases</th>
<th>AN BINGE-PURGE subtype cases</th>
<th>Controls (% of females)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Discovery dataset</strong>*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Canada</td>
<td>54</td>
<td>24</td>
<td>25</td>
<td>417 (46.52)</td>
</tr>
<tr>
<td>Czech Republic</td>
<td>72</td>
<td>40</td>
<td>29</td>
<td>331 (35.04)</td>
</tr>
<tr>
<td>Finland</td>
<td>131</td>
<td>39</td>
<td>29</td>
<td>404 (100)</td>
</tr>
<tr>
<td>France</td>
<td>293</td>
<td>137</td>
<td>135</td>
<td>619 (60.09)</td>
</tr>
<tr>
<td>Germany</td>
<td>475</td>
<td>147</td>
<td>55</td>
<td>1,205 (49.13)</td>
</tr>
<tr>
<td>Greece</td>
<td>70</td>
<td>10</td>
<td>5</td>
<td>79 (100)</td>
</tr>
<tr>
<td>Italy-North</td>
<td>203</td>
<td>103</td>
<td>99</td>
<td>841 (52.19)</td>
</tr>
<tr>
<td>Italy-South</td>
<td>75</td>
<td>31</td>
<td>26</td>
<td>52 (100)</td>
</tr>
<tr>
<td>Netherlands</td>
<td>348</td>
<td>115</td>
<td>90</td>
<td>593 (51.26)</td>
</tr>
<tr>
<td>Norway</td>
<td>82</td>
<td>24</td>
<td>15</td>
<td>602 (67.44)</td>
</tr>
<tr>
<td>Poland</td>
<td>175</td>
<td>68</td>
<td>107</td>
<td>564 (29.43)</td>
</tr>
<tr>
<td>Spain</td>
<td>186</td>
<td>45</td>
<td>44</td>
<td>185 (75.14)</td>
</tr>
<tr>
<td>Sweden</td>
<td>39</td>
<td>28</td>
<td>11</td>
<td>975 (72.10)</td>
</tr>
<tr>
<td>UK</td>
<td>213</td>
<td>97</td>
<td>97</td>
<td>5,163 (49.43)</td>
</tr>
<tr>
<td>USA</td>
<td>491</td>
<td>311</td>
<td>165</td>
<td>2,830 (41.31)</td>
</tr>
<tr>
<td><strong>Total discovery</strong></td>
<td>2,907</td>
<td>1,219</td>
<td>932</td>
<td>14,860 (51.73)</td>
</tr>
</tbody>
</table>

*In silico replication*

<table>
<thead>
<tr>
<th>Country</th>
<th>Cases (% of females)</th>
<th>AN RESTRICTING subtype cases</th>
<th>AN BINGE-PURGE subtype cases</th>
<th>Controls (% of females)</th>
</tr>
</thead>
<tbody>
<tr>
<td>USA-Hakonarson</td>
<td>1,033 (97.67)</td>
<td>0</td>
<td>0</td>
<td>3,775 (45.85)</td>
</tr>
<tr>
<td>Estonia</td>
<td>313 (100)</td>
<td>0</td>
<td>0</td>
<td>106 (100)</td>
</tr>
</tbody>
</table>

*De novo replication*

<table>
<thead>
<tr>
<th>Country</th>
<th>Cases (% of females)</th>
<th>AN RESTRICTING subtype cases</th>
<th>AN BINGE-PURGE subtype cases</th>
<th>Controls (% of females)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Austria</td>
<td>48 (100)</td>
<td>0</td>
<td>0</td>
<td>183 (65.03)</td>
</tr>
<tr>
<td>Czech Republic</td>
<td>32 (71.88)</td>
<td>0</td>
<td>0</td>
<td>22 (100)</td>
</tr>
<tr>
<td>Finland</td>
<td>15 (100)</td>
<td>0</td>
<td>0</td>
<td>94 (8.51)</td>
</tr>
<tr>
<td>France</td>
<td>55 (100)</td>
<td>0</td>
<td>0</td>
<td>123 (100)</td>
</tr>
<tr>
<td>Germany</td>
<td>174 (99.43)</td>
<td>31</td>
<td>64</td>
<td>380 (66.84)</td>
</tr>
<tr>
<td>Greece</td>
<td>16 (100)</td>
<td>0</td>
<td>0</td>
<td>53 (100)</td>
</tr>
<tr>
<td>Italy-South</td>
<td>156 (96.79)</td>
<td>32</td>
<td>24</td>
<td>63 (100)</td>
</tr>
<tr>
<td>Netherlands</td>
<td>229 (100)</td>
<td>45</td>
<td>23</td>
<td>380 (27.11)</td>
</tr>
<tr>
<td>Poland</td>
<td>52 (98.08)</td>
<td>0</td>
<td>0</td>
<td>93 (100)</td>
</tr>
<tr>
<td>Spain</td>
<td>10 (100)</td>
<td>0</td>
<td>0</td>
<td>328 (41.46)</td>
</tr>
<tr>
<td>UK</td>
<td>155 (100)</td>
<td>28</td>
<td>55</td>
<td>199 (65.83)</td>
</tr>
<tr>
<td>USA**</td>
<td>671 (100)</td>
<td>349</td>
<td>272</td>
<td>2,830 (41.31)</td>
</tr>
<tr>
<td>Japan</td>
<td>458 (100)</td>
<td>213</td>
<td>240</td>
<td>421 (100)</td>
</tr>
<tr>
<td><strong>Total replication</strong></td>
<td>3,135 (98.72)</td>
<td>698</td>
<td>678</td>
<td>9,050 (50.08)</td>
</tr>
<tr>
<td>Country</td>
<td>Cases (% of females)</td>
<td>AN RESTRICTING subtype cases</td>
<td>AN BINGE-PURGE subtype cases</td>
<td>Controls (% of females)</td>
</tr>
<tr>
<td>--------------------</td>
<td>----------------------</td>
<td>-----------------------------</td>
<td>-----------------------------</td>
<td>------------------------</td>
</tr>
<tr>
<td>Total global meta-analysis</td>
<td>5,551</td>
<td>1,606</td>
<td>1,445</td>
<td>21,080</td>
</tr>
</tbody>
</table>

* All AN cases from discovery dataset were females.

** USA samples from discovery dataset were merged together with USA replication samples for replication analysis. The same USA control dataset was used.
Table 2
Global meta-analysis results of SNPs with the greatest evidence of association for the main anorexia nervosa (AN) case-control analysis

<table>
<thead>
<tr>
<th>CHR</th>
<th>POS</th>
<th>MARKER</th>
<th>NEAREST GENE</th>
<th>EA</th>
<th>NEA</th>
<th>EAF</th>
<th>OR</th>
<th>OR_95L</th>
<th>OR_95U</th>
<th>P</th>
<th>I²</th>
<th>N_st</th>
<th>N_sa</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>182794261</td>
<td>rs9839776</td>
<td><strong>SOX2OT</strong></td>
<td>T</td>
<td>C</td>
<td>0.270</td>
<td>1.158</td>
<td>1.095</td>
<td>1.225</td>
<td>3.01E-07</td>
<td>0</td>
<td>27</td>
<td>21857</td>
</tr>
<tr>
<td>4</td>
<td>102267099</td>
<td>rs17030795</td>
<td><strong>PPP3CA</strong></td>
<td>G</td>
<td>A</td>
<td>0.192</td>
<td>1.149</td>
<td>1.082</td>
<td>1.220</td>
<td>5.84E-06</td>
<td>0</td>
<td>24</td>
<td>23111</td>
</tr>
<tr>
<td>8</td>
<td>19584542</td>
<td>rs11204064</td>
<td><strong>CSGALNACT1</strong></td>
<td>G</td>
<td>A</td>
<td>0.477</td>
<td>1.118</td>
<td>1.063</td>
<td>1.176</td>
<td>1.57E-05</td>
<td>0.008</td>
<td>28</td>
<td>21477</td>
</tr>
<tr>
<td>3</td>
<td>12013264</td>
<td>rs2618405</td>
<td>7.5kb from <strong>SYN2</strong></td>
<td>C</td>
<td>A</td>
<td>0.218</td>
<td>1.152</td>
<td>1.079</td>
<td>1.229</td>
<td>2.03E-05</td>
<td>0.244</td>
<td>22</td>
<td>18566</td>
</tr>
<tr>
<td>13</td>
<td>23433988</td>
<td>rs1867979</td>
<td>18kb from <strong>SPATA13</strong></td>
<td>T</td>
<td>C</td>
<td>0.301</td>
<td>1.133</td>
<td>1.070</td>
<td>1.200</td>
<td>2.18E-05</td>
<td>0.317</td>
<td>25</td>
<td>15827</td>
</tr>
<tr>
<td>21</td>
<td>21257379</td>
<td>rs10482915</td>
<td>35kb from <strong>NCAM2</strong></td>
<td>A</td>
<td>G</td>
<td>0.074</td>
<td>1.193</td>
<td>1.097</td>
<td>1.297</td>
<td>3.96E-05</td>
<td>0</td>
<td>28</td>
<td>26164</td>
</tr>
<tr>
<td>7</td>
<td>106473684</td>
<td>rs2395833</td>
<td><strong>PRKAR2B</strong></td>
<td>T</td>
<td>G</td>
<td>0.334</td>
<td>1.101</td>
<td>1.051</td>
<td>1.154</td>
<td>5.62E-05</td>
<td>0.132</td>
<td>29</td>
<td>26511</td>
</tr>
<tr>
<td>2</td>
<td>80768625</td>
<td>rs1370359</td>
<td>39kb from <strong>CTNNA2</strong></td>
<td>C</td>
<td>T</td>
<td>0.472</td>
<td>1.098</td>
<td>1.049</td>
<td>1.149</td>
<td>5.68E-05</td>
<td>0</td>
<td>29</td>
<td>26508</td>
</tr>
<tr>
<td>13</td>
<td>63470128</td>
<td>rs9539891</td>
<td>255kb from <strong>OR7E156P</strong></td>
<td>C</td>
<td>T</td>
<td>0.332</td>
<td>0.891</td>
<td>0.842</td>
<td>0.942</td>
<td>5.88E-05</td>
<td>0</td>
<td>23</td>
<td>20389</td>
</tr>
<tr>
<td>2</td>
<td>225017222</td>
<td>rs1529212</td>
<td>26kb from <strong>CUL3</strong>/42kb from <strong>FAM124B</strong></td>
<td>T</td>
<td>C</td>
<td>0.210</td>
<td>1.131</td>
<td>1.065</td>
<td>1.201</td>
<td>5.95E-05</td>
<td>0.162</td>
<td>26</td>
<td>21858</td>
</tr>
<tr>
<td>19</td>
<td>11650015</td>
<td>rs206863</td>
<td><strong>ZNF833P</strong></td>
<td>A</td>
<td>G</td>
<td>0.899</td>
<td>0.864</td>
<td>0.804</td>
<td>0.928</td>
<td>6.47E-05</td>
<td>0.076</td>
<td>28</td>
<td>26402</td>
</tr>
<tr>
<td>23</td>
<td>107578961</td>
<td>rs5929098</td>
<td><strong>COLA45</strong></td>
<td>T</td>
<td>C</td>
<td>0.771</td>
<td>1.135</td>
<td>1.066</td>
<td>1.210</td>
<td>8.37E-05</td>
<td>0.002</td>
<td>29</td>
<td>19249</td>
</tr>
<tr>
<td>7</td>
<td>146565029</td>
<td>rs6940268</td>
<td><strong>CNTNAP2</strong></td>
<td>A</td>
<td>G</td>
<td>0.097</td>
<td>1.161</td>
<td>1.077</td>
<td>1.251</td>
<td>9.38E-05</td>
<td>0</td>
<td>29</td>
<td>26377</td>
</tr>
</tbody>
</table>

CHR - chromosome; POS - position in hg18; EA - effect allele; NEA - non-effect allele; EAF - effect allele frequency; OR - odds ratio; OR_95L - lower 95% confidence interval; OR_95U - upper 95% confidence interval; P - p-value; I² - measure of heterogeneity; N_st - number of contributing studies; N_sa - number of contributing samples.